Lion Biotechnologies Announces Publication of Data From Clinical Study of Metastatic Cervical Cancer Patients Treated With HP...
April 08 2015 - 8:26AM
Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company
that is developing novel cancer immunotherapies based on
tumor-infiltrating lymphocytes (TIL), today announced that data
from a metastatic cervical cancer study conducted by the National
Cancer Institute (NCI) was published in the Journal of Clinical
Oncology in an article titled "Complete Regression of Metastatic
Cervical Cancer After Treatment With Human Papillomavirus-Targeted
Tumor-Infiltrating T Cells". Data from the trial showed objective
responses, including durable, complete regressions, in patients
after a single infusion of HPV-TIL.
The trial was designed to determine if the infusion of human
papillomavirus tumor-infiltrating lymphocytes (HPV-TIL) could
induce regression of advanced HPV-positive cancers.
Of the nine metastatic cervical cancer patients who were
enrolled and treated with HPV-TIL, three patients experienced
objective tumor responses, two of whom experienced complete,
ongoing remissions of 22 and 15 months, respectively. The other
patient demonstrated a partial response of three months.
"We are pleased to see the results of this trial, which
demonstrate potential efficacy of TIL treatment in metastatic
cervical cancer, a notoriously difficult-to-treat cancer in women,"
said Elma Hawkins, PhD, Lion's president and chief executive
officer. "We recently amended our CRADA with the NCI to include
technologies based on the HPV-TIL research. With these
technologies, we look forward to expanding our clinical programs
and developing new treatment options for patients with cervical
cancer and other solid tumors."
About Lion Biotechnologies
Lion Biotechnologies, Inc. is engaged in the development of T
cells and engineered T cells for the treatment of various cancers.
The company's lead product candidate, LN-144, is a ready-to-infuse,
autologous T-cell therapy utilizing tumor-infiltrating lymphocytes
(TIL) for the treatment of patients with metastatic melanoma, and
is based on a clinical Cooperative Research and Development
Agreement with the National Cancer Institute. TIL therapy is also
being evaluated in physician-sponsored clinical trials at MD
Anderson Cancer Center and Moffitt Cancer Center. For more
information, please visit http://www.lionbio.com.
Forward Looking Statements
This press release contains certain forward-looking statements
that are subject to a number of risks and uncertainties, including
the uncertainty relating to the efficacy of TIL treatment in
metastatic cervical cancer and the Company's ability to file an IND
application with the FDA for clinical studies in solid tumor types,
such as cervical cancer. Additional risks and uncertainties are
described in the Company's most recently filed quarterly report on
Form 10-Q and annual report on Form 10-K. Except as permitted by
law, the Company undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACT: Investor Relations
The Trout Group
Tricia Truehart
646-378-2953
ttruehart@troutgroup.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2023 to Apr 2024